drugset
drugset / Trial / NCT03399214

Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

NCT03399214 ↗

Phase 1 Completed 12 enrolled MegaPro Biomedical Co. Ltd.
RandomizedSequentialOpen-labelDiagnostic

Summary

The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.

Timeline

Start
2018-04-01
Primary completion
2018-05-01
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IOP Injection Unknown 0.27 mg/kg Intravenous
Subject IOP Injection Unknown 0.54 mg/kg Intravenous

Indications

No indication recorded.